Virtus Biotech Clinical Trials ETF
10 hedge funds and large institutions have $8.4M invested in Virtus Biotech Clinical Trials ETF in 2017 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 8 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
2% more capital invested
Capital invested by funds: $8.24M → $8.4M (+$158K)
6.85% less ownership
Funds ownership: 34.29% → 27.44% (-6.8%)
44% less funds holding
Funds holding: 18 → 10 (-8)
88% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPL Financial
San Diego,
California
|
+$459K |
| 2 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
+$61.1K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$53.8K |
| 4 |
CCP
Cardan Capital Partners
Denver,
Colorado
|
+$16.4K |
| 5 |
AWM
Avior Wealth Management
Omaha,
Nebraska
|
+$12.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SG Americas Securities
New York
|
-$818K |
| 2 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$290K |
| 3 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
-$224K |
| 4 |
Goldman Sachs
New York
|
-$33.6K |
| 5 |
Creative Planning
Overland Park,
Kansas
|
-$18K |
BBC Hedge Fund Activity: Q3 2017 in Review
10 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech Clinical Trials ETF (BBC) for Q3 2017, worth a combined $8.4M — up 1.9% from $8.24M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of BBC and 1 opened new positions — a net loss of 7 holders — while 1 trimmed existing stakes and 4 added.
The largest buyer was LPL Financial, adding an estimated $459K. The largest seller was SG Americas Securities, exiting entirely with an estimated $818K sold.
- 10 institutional investors held Virtus Biotech Clinical Trials ETF (BBC) as of Q3 2017, down from 18 in Q2 2017.
- Funds reported $8.4M of Virtus Biotech Clinical Trials ETF stock for Q3 2017, up 1.9% quarter-over-quarter.
- 1 fund opened new Virtus Biotech Clinical Trials ETF positions in Q3 2017 and 8 closed out, a net change of -7 holders.
- The largest Virtus Biotech Clinical Trials ETF buyer in Q3 2017 was LPL Financial, an estimated $459K added.
- The largest Virtus Biotech Clinical Trials ETF seller in Q3 2017 was SG Americas Securities, an estimated $818K sold.
Based on aggregated 13F filings for Q3 2017.